Local Thrombolytics Before Thrombectomy in STEMI (DISSOLUTION)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01568931|
Recruitment Status : Unknown
Verified March 2013 by Francesco Pelliccia, University of Roma La Sapienza.
Recruitment status was: Not yet recruiting
First Posted : April 2, 2012
Last Update Posted : March 7, 2013
Background Prompt reperfusion with percutaneous coronary intervention (PCI) in the setting of ST-elevation myocardial infarction (STEMI) improves clinical outcomes through salvage of myocardial tissue.
Although the use of thrombus aspiration with PCI can result in improved rates of normal epicardial flow and myocardial perfusion, several unmet needs remain.
Purpose The purpose of this trial will be to evaluate the hypothesis that local delivery of thrombolytics vs. saline infusion prior to thrombus aspiration and PCI is safe and effective in patients with STEMI.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Drug: Urokinase Drug: Saline||Phase 4|
The study will select patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing manual thrombectomy followed by primary percutaneous coronary intervention (PCI).
Patients will be randomized to receive local bolus of 200,000 units urokinase or saline solution
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2017|
Active Comparator: Urokinase
Patients will be randomized to to receive local bolus of 200,000 units urokinase
intracoronary, urokinase, 200,000 Units, bolus
Other Name: UROKINASE-R, IMARX THERAPEUTICS INC., Tucson, AZ
Active Comparator: Saline
Patients will be randomized to to receive local bolus of intracoronary saline
intracoronary, saline, bolus 1 cc
Other Name: Saline infusion
- MACE at 30 days [ Time Frame: Up to 30 days ]30-day Major adverse cardiac events (MACE), defined as the occurrence of death, new Q-wave myocardial infarction, coronary artery bypass grafting, target lesion revascularization, stroke, or stent thrombosis
- Myocardial reperfusion after Primary CI [ Time Frame: Up to 90 minutes after Primary PCI ]ST-segment resolution (STR)>70% as assessed 90 minutes after Primary PCI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01568931
|Contact: Gaetano Tanzilli, MD||+39064997 ext email@example.com|
|Contact: Francesco Pelliccia, MD||+39064997 ext firstname.lastname@example.org|
|Study Director:||Cesare Greco, MD||University Sapienza|